Ono And Astellas Obtain Approval For Osteoporosis Drug
This article was originally published in PharmAsia News
Executive Summary
Osaka based Ono Pharmaceutical and Tokyo based Astellas announced Jan. 21 that osteoporosis drug RECALBON/Bonoteo (minodronic acid) obtained manufacturing and marketing approval from Japan's Ministry of Health, Labor and Welfare on the same date. Jointly developed by the two companies, the new drug application was filed in July 2006. ( href='http://www.jiji.com/jc/c?g=ind_30&k=2009012100641'>Click here for more Japanese language